Evaluation of analgesic effects of intravenous metoclopramide versus intravenous ketorolac in patients with primary acute headache

Evaluation of analgesic effects of intravenous metoclopramide versus intravenous ketorolac in patients with primary acute headache (migraines, tension, cluster) in emergency department: a double-blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151103024853N4

Enrollment

Registered

2020-08-13

Start date

2019-02-20

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Migraine. Condition 2: Tension-type headache. Condition 3: Cluster headaches. Migraine Tension-type headache Cluster headaches and other trigeminal autonomic cephalgias (TAC)

Interventions

Intervention 1: Intervention group: After receiving the baseline VAS score from patients, 30 mg ketorolac plus 50 ml of normal saline were infused for 15 minutes. VAS Score, response to treatment and

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients referring to the emergency department with acute primary headache (migraine, tension, cluster) Age: minimum 18 years old and maximum 65 years old

Exclusion criteria

Exclusion criteria: Pregnancy Nursing mothers Any active bleeding CHF (Congestive Heart Failure) MI (Myocardial Infarction) history Parkinson or history of any Extrapyramidal Side Effects Pheochromocytoma Epilepsy and history of seizure History of Depression Allergy to experimented drugs Painkillers administration before admission to the Emergency Department (ED) ??Systolic Blood pressure under 90mmHg or above 180mmHg Heart rate under 50 beats/min or above 150 beats/min Patients taking Antipsychotics, Promethazine, MAO inhibitors, Rivastigmine

Design outcomes

Primary

Measure	Time frame
Pain Visual Analogue Scale (VAS Scoring). Timepoint: Baseline, 15, 30, 60 minutes after intervention. Method of measurement: 10-cm visual analog pain scale.	—

Secondary

Measure	Time frame
Patients achieved headache freedom in the ED without requiring rescue medication. Timepoint: 60 minutes after intervention. Method of measurement: Patients own statement of Headache freedom.;Patients that required rescue medication in the ED. Timepoint: 60 minutes after intervention. Method of measurement: Minor headache improvement in patients with the discretion of the treating physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Leila Kouti

Ahvaz University of Medical Sciences

lkouti.pharmacotherapy@gmail.com+98 61 3373 8380

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026